Table 2.

Ruxolitinib responses

Acute GVHD (n = 23)	ORR	CRR
Overall response	16/23 (69.5)	5/23 (21.7)
Response rate in grades 3–4	14/20 (70)	5/20 (25)
RR by organs
Skin	11/16 (68.8)	3/16 (18.7)
Gut	14/21 (66.7)	4/21 (19)
Liver	9/13 (69.2)	3/13 (23)
RR ≥ 3 lines of treatment	9/12 (75)
And aGVHV grades 3–4	8/11 (72.7)	2/11 (18.2)
And skin involvement	8/10 (80)	2/9 (20)
And gut involvement	8/11 (72.7)	1/11 (9)
And liver involvement	4/6 (66.7)	1/6 (16)

Chronic GVHD (n = 56)	ORR	CRR
Overall response	32/56 (57.1)	2/56 (3.5)
RR by grades
Moderate	17/28 (60.7)	1/28 (3.5)
Severe	15/28 (53.5)	1/28 (3.5)
RR by organs
Skin with sclerotic changes	14/25 (56)	0/25 (0)
Lung	16/26 (61.5)	2/26 (7)
Gut	9/16 (56.3)	2/16 (12)
RR ≥3 lines of treatment	17/32 (53.1)	2/32 (6.3)
And moderate plus severe	17/32 (53.1)	2/32 (6.3)
cGVHD
And skin involvement with sclerotic changes	8/15 (53.3)	0/15 (0)
And lung involvement	10/14 (71.4)	2/14 (14.2)
And gut involvement	7/10 (70)	2/10 (20)